Log in
Enquire now
‌

US Patent 10058522 Oxidative retinal diseases

Patent 10058522 was granted and assigned to Retrotope Inc. on August, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Retrotope Inc.
Retrotope Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10058522
Date of Patent
August 28, 2018
Patent Application Number
14113547
Date Filed
April 24, 2012
Patent Citations Received
‌
US Patent 12109194 Synergistic combination therapy for treating ALS
0
‌
US Patent 11510888 Alleviating oxidative stress disorders with PUFA derivatives
‌
US Patent RE49238 Alleviating oxidative stress disorders with PUFA derivatives
Patent Primary Examiner
‌
Lynn Y Fan
Patent abstract

Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10058522 Oxidative retinal diseases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.